ImmuneBridge

San Francisco, CA · Founded 2018 · Privately Held (backing)

Developer of allogeneic cellular immunotherapies designed for advancing cancer treatment. ImmuneBridge is based in San Francisco, CA and was founded in 2018. Its last reported valuation was $25 million in Jan 2023. It has raised $19.7 million across 2 recorded rounds; the latest was a $5.6 million early-stage round in Mar 2025.

Last reported valuation
$25.0M
Oct 2026
Priced at
—
Total raised
$19.7M
Last round
Early Stage VC
Mar 2025

Who backs ImmuneBridge?

16 investors
InvestorType
Pioneer FundVenture capital
Insight Partners (New York)PE / buyout
GaingelsVenture capital
Calm VenturesVenture capital
Endless Frontier Labs—
Quiet Capital—
NFXVenture capital
Sand Hill AngelsVenture capital
M VenturesVenture capital
One Way VenturesVenture capital
+ 6 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

ImmuneBridge investors

16 investors are on record for ImmuneBridge, including Pioneer Fund, Insight Partners (New York), Gaingels and Calm Ventures. By type, the record holds 7 venture capital firms and 1 private equity firm. The early-stage round in Mar 2025 drew 6 investors.

Free account
More of ImmuneBridge with a free account
  • ·The complete investor list: 16 names
  • ·Watch ImmuneBridge: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 16 firms already write checks for companies like ImmuneBridge. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View